Female, 47 y/o

Patient internal ID: 289422365

ICD-10 code

C50.8 Malignant Neoplasm of Overlapping Sites of Breast

Diagnosis (incl metastases/stage) and year

September 2020
Carcinoma of the Left Breast cT2N2M0, G2 ER(-), PR(-), HER2(-), Ki67-75%, stage IIIA, BRCA2 Gene Mutation. Post Neoadjuvant Chemotherapy (2021-03) and Bilateral Mastectomy ypT0 N1a
M0 LVI-1 R0.

Previous treatment

Surgery, Chemotherapy (Paclitaxel, Carboplatin), Chemotherapy (Capecitabine), Radiation Therapy.

Prognosis and survival expectation

The estimated Five-Year Triple-Negative Breast Cancer survival rate with Regional Spread is 65.4% (SEER).

Treatment provided

Autologous DCV (5 doses) and CIK (4 doses) over a period of 9 months. Additionally, the patient received Umbilical Cord Blood Derived NK Cells (4 doses), Immunostimulation of Interferon (IFN) β and Tumor Necrosis Factor (TNF).

Patient survival/condition and year

The patient is alive (now 37 months since diagnosis), without disease progression. The patient continues follow-up care every 6 months. It can be concluded that the addition of Immunotherapy, alongside, Surgery, Chemotherapies and Radiation Therapy, has benefited the patient with stable disease and disease control.

Date of Review